Rasburicase

Generic Name: Rasburicase

Brand Names: Elitek, Fasturtec

Drug Type: Biotech

Chemical Formula: -

CAS Number: 134774-45-1

Unique Ingredient Identifier: 08GY9K1EUO

Background: Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.

Indication: For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)

Associated Conditions: Hyperuricemia

Associated Therapies: -

Clinical Trials

Rasburicase Treatment in Chronic Gouty Arthritis

Phase 4

Recruiting

Conditions: Chronic Gout

Interventions: Drug: Rasburicase

First Posted Date: 2022-04-05

Last Posted Date: 2023-05-09

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 60

Registration Number: NCT05312268

Locations: 🇨🇳
Shenshan Medical Center, Shanwei, Guangdong, China
🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Shunde Hospital of Southern Medical University, Foshan, Guangdong, China

and more 1 locations

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Phase 4

Recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Tumor Lysis Syndrome

Interventions: Drug: Pegloticase
Drug: Rasburicase

First Posted Date: 2021-02-09

Last Posted Date: 2024-12-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT04745910

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Uric Acid Effects on Endothelium and Oxydative Stress

Not Applicable

Completed

Conditions: Oxidative Stress
Endothelial Function
Cardiovascular System
Hypertension

Interventions: Drug: Placebos
Drug: Febuxostat
Drug: Rasburicase

First Posted Date: 2018-01-10

Last Posted Date: 2020-02-28

Lead Sponsor: Erasme University Hospital

Target Recruit Count: 53

Registration Number: NCT03395977

Locations: 🇧🇪
Erasme Hospital, Brussels, Belgique, Belgium

Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status

Not Applicable

Completed

Conditions: Obesity
Metabolic Syndrome
Hyperuricemia

Interventions: Drug: Rasburicase

First Posted Date: 2013-08-29

Last Posted Date: 2018-08-14

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 31

Registration Number: NCT01931527

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Phase 2

Terminated

Conditions: Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Blastic Phase Chronic Myelogenous Leukemia
Contiguous Stage II Adult Burkitt Lymphoma
de Novo Myelodysplastic Syndromes
Recurrent Adult Burkitt Lymphoma
Untreated Adult Acute Lymphoblastic Leukemia
Untreated Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Previously Treated Myelodysplastic Syndromes
Stage III Adult Burkitt Lymphoma

Interventions: Drug: rasburicase
Drug: allopurinol

First Posted Date: 2012-03-27

Last Posted Date: 2018-01-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 24

Registration Number: NCT01564277

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Phase 2

Completed

Conditions: Lymphoma
Leukemia

Interventions: Drug: Rasburicase
Drug: Allopurinol

First Posted Date: 2010-09-13

Last Posted Date: 2020-01-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 55

Registration Number: NCT01200485

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lowering Serum Uric Acid to Prevent Acute Kidney Injury

Phase 2

Completed

Conditions: Hyperuricemia

Interventions: Drug: Placebo
Drug: Rasburicase

First Posted Date: 2008-09-22

Last Posted Date: 2012-09-03

Lead Sponsor: University of Florida

Target Recruit Count: 26

Registration Number: NCT00756964

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States

Fasturtec TLS Treatment / Prophylysis

Phase 4

Completed

Conditions: Tumor Lysis Syndrome

First Posted Date: 2008-04-03

Last Posted Date: 2008-04-03

Lead Sponsor: Sanofi

Target Recruit Count: 45

Registration Number: NCT00651911

Locations: 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States

Rasburicase (Fasturtec) Registration Trial

Phase 3

Terminated

Conditions: Hyperuricemia

Interventions: Drug: Allopurinol
Drug: Rasburicase

First Posted Date: 2008-02-05

Last Posted Date: 2014-05-08

Lead Sponsor: Sanofi

Target Recruit Count: 10

Registration Number: NCT00607152

Locations: 🇨🇳
Sanofi-Aventis Administrative Office, Shanghai, China

Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome

Phase 4

Completed

Conditions: Hyperuricemia

First Posted Date: 2007-11-26

Last Posted Date: 2008-01-28

Lead Sponsor: Sanofi

Target Recruit Count: 38

Registration Number: NCT00563771

Locations: 🇰🇷
Sanofi-Aventis, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy